Form 4: Arrowhead Pharmaceuticals Director Sells Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals director Douglas B. Given sold a total of 5,547 shares of common stock in two transactions on December 16th and 17th, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Douglas B. Given, a director at Arrowhead Pharmaceuticals, sold 5,000 shares of common stock on December 16, 2024, at a weighted average price of $21.90 per share.
• The shares were sold in multiple transactions with prices ranging from $21.64 to $22.20.
• On December 17, 2024, Mr. Given sold an additional 547 shares at a price of $22.04 per share.
• These sales were executed under a pre-arranged 10b5-1 trading plan.
• The transactions also included a partial disposition of Restricted Stock Units (RSUs) to cover tax withholding obligations.
• Following these transactions, Mr. Given beneficially owns 124,167 shares of Arrowhead Pharmaceuticals common stock, which includes shares underlying unvested RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors.

Comparison to Industry Standards

• Sales under 10b5-1 plans are a common practice among corporate insiders to avoid accusations of trading on non-public information.
• The volume of shares sold is relatively small compared to the total outstanding shares of Arrowhead Pharmaceuticals, suggesting it is not a major market event.
• Similar sales are often seen in other biotech companies, where stock-based compensation is a significant part of executive pay.

Stakeholder Impact

• The impact on shareholders is likely to be minimal, as the sales were conducted under a pre-arranged plan and the volume is not significant.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, insider trading, Form 4, Douglas B. Given, 10b5-1 plan, stock sale, director, restricted stock units, RSU